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Summary
As an international collaboration between the Hungarian Pediatric Society and the Polish Foundation for the Development of 
Paediatrics, multidisciplinary expert group meeting was organized to analyze the current situation and the results of the work 
performed on varicella prevention in Poland and in Hungary (ie. burden of disease, public health considerations of primary 
preventive technologies), and to discuss the possible modification in vaccination practice based on the US and German experi-
ence and health economic considerations. 
Varicella (chickenpox) is a highly contagious disease predominantly affecting children aged 1-9 years, and approximately 
80-90% of children are seropositive for VZV by the age of 15 years. In 2-6% of all cases potentially serious complications can 
occur in previously healthy children and adults. According to the European surveillance network, European population is highly 
**Summary of Expert Working Group Meeting. The members of Expert Working Group Meeting: Z. Kaló, A. Kulcsár, Zs. Mész-
ner, Zs. Molnár, L. Szabó, (Hungary), T. Jackowska, P. Stefanoff, J. Wysocki (Poland), P. Wutzler (Germany) and C. Sauboin 
(Belgium). The meeting took place in Budapest, on the 26th of September under the title: Varicella Vaccination in Hungary and 
Poland – Optimization of public benefits from prophylaxis technologies in the time of austerity
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infected by VZV, and vaccine uptake is extremely poor. Routine childhood immunization against varicella may be considered 
in countries where (1) varicella is relatively important public health and socioeconomic problem; (2) vaccine is affordable; and 
(3) high and sustained vaccine coverage can be achieved. Even in difficult economic periods, when health care budgets are seri-
ously limited, further resources for primary prevention should be found, which would also enable children from all economic 
backgrounds to receive vaccination on an equal basis. Ideal reimbursement strategy would be full (100%) coverage by giving 
two doses for one or more cohorts. If it is not feasible second best option would be a partial reimbursement scheme for every 
child. In case it could not be reached, reimbursement only for risk groups should be implemented in Hungary (this is already 
available in Poland). As long-term evidence is not available at the time of registration, health economic modelling is required. 
Modelling with thorough sensitivity analysis can reduce the uncertainty of reimbursement decisions compared to alternative 
use of public resources.
Key words: varicella, vaccination
INTRODUCTION
Though the problem of the vaccine preventable dis-
eases should be nearly completely solved all over the 
world, the access to modern immunization possibilities 
has been challenged.
Fortunately, varicella is a mild infection in most cas-
es. However, in 2-6% of all the cases potentially serious 
complications can occur in previously healthy children 
and adults (1). Varicella is a highly contagious disease 
predominantly affecting children aged 1-9 years, and ap-
proximately 80-90% of children are seropositive for VZV 
by the age of 15 years (2). Varicella and related immedi-
ate and long-term complications put a significant medi-
cal-economic pressure on national health systems.
Vaccines against VZV infection have been for years 
available in both Hungary and Poland. Polish and Hun-
garian experts in vaccinology prepared the recommen-
dation several years ago, varicella infection has been 
discussed atlocal pediatric conferences, and studies 
about disease morbidity and complications have been 
published in local medical journals (3-8). Parents and 
communities (kindergartens, schools etc.) have been 
educated in TV programs, web pages, with leaflets; the 
vaccine uptake, however, is far from optimal. Epidemi-
ology has not changed and the incidence in Europe is 
still high.
EPIDEMIOLOGICAL BACKGROUND IN EUROPE
European varicella surveillance data isavailable on 
the website of the European surveillance network for se-
lected vaccine preventable diseases hosted in Sweden 
by the European CDC (www.euvac.net). This network 
collects age-specific data including vaccination status, 
laboratory confirmation, hospitalization and complica-
tion rate from 19 countries (fig. 1).
In 2008, 2009 and 2010 almost 900,000 varicella cas-
es were reported from 19 countries. In 2010, 99.5% of all 
varicella patients were unvaccinated, and patients with 
breakthrough infection (0.5%) had received at least one 
dose. These data indicates that Europe seems to have a 
high prevalence of VZV infections and that vaccine up-
take seems to be poor.
Of note, Poland was the country to report most vari-
cella cases of all cases in Europe (n = 183 446 (2010)), 
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with 59% (2008-2009) and 31% (2010) (Varicella surveil-
lance report 2010; www. euvac.net).
VZV prevention in Hungary
In Hungary, the incidence of vaccine preventable 
diseases has decreased only for those diseases where 
a compulsory vaccination schedule exists. For decades 
an age-related vaccination calendar of National Immu-
nization Program (NIP) has been successfully followed 
in Hungary. Compulsory vaccines get complete reim-
bursement of the Ministry of Health and have achieved 
98% vaccination coverage. Unfortunately, there has 
not been any modernization in the calendarfrom 2009 
to date, whereas in other countries several new vac-
cines have been introduced as part of the immuniza-
tion scheme. Vaccines not included in the calendar are 
optional, and some of them are partially reimbursed. 
However, the incidence of vaccine preventable dis-
eases as varicella and tick-born encephalitis has not 
changed significantly in the last few years. These vac-
cines are available only in the private market with low 
coverage and consequently no significant epidemio-
logical impact. In the last year (2010) 39.602 varicella 
cases (with no death) were reported. 
Varicella vaccine has beenavailable since 2003, 
however in the private market only. As a consequence, 
its vaccination coverage is very poor (about 20%), and 
only a small percentage of immunized persons have 
received two shots. In spite of the efforts performed 
since 2003 (recommendations, continuous profes-
sional and parental education) the number of people 
vaccinated has reached a plateau, so new strategies 
are needed to further increase the awareness for the 
disease.
VZV prevention in Poland
After a peak in the early 1990s, the number of new 
varicella cases has increased since 2006-2007. Mean-
while the number of vaccinated person hadshown a 
constant increase since 2006 from 8,000 to 30,000 cas-
es in 2010 − mostly financed by parents, except in risk 
groups, where it has been covered by the government 
as compulsory vaccination − still with no epidemiologi-
cal impact.
Poland has a very similar vaccination system to 
Hungary and other post-Soviet countries. According 
to the regulation that was introduced in 2008, children 
below 12 years of age receive mandatory vaccination 
against varicella if they are part of the following risk 
groups9: (1) immunocompromised, with a high-risk 
of severe disease; (2) with acute lymphoblastic leu-
kaemia in the remission period; (3) with HIV; (4) be-
fore immunosuppressive treatment or chemotherapy; 
(5) children until 12 years of age from an environment 
of people described in point 1) who have not devel-
oped varicella yet; and from October 2011 (6) chil-
dren until 12 years of age other than in point 1) to 5) 
vulnerable to an infection because of environmental 
reasons, especially those vulnerable because of living 
in common spaces which enables virus transmission 
and an outbreak occurrence, including mainly long-
term care homes, orphanages, day nurseries and 
other care institutions.
In both countries, the epidemiological situation which 
is representative for other European countries shows 
similar tendencies without improvement using the cur-
rent prevention methods. To achieve changes, interna-
tional recommendations and successful programs with 
varicella vaccination as UMV (universal mass vaccina-
tion) are available. 
WHO recommendation for VZV vaccination
According to the WHO recommendation, routine 
childhood immunization against varicella may be con-
sidered in countries where (1) varicella is a relatively 
important public health and a socioeconomic prob-
lem; (2) vaccination is affordable; and (3) high and 
sustained vaccine coverage can be achieved. In ad-
dition, vaccination should be offered in any country 
to individual adolescents and adults without a history 
of varicella, in particular to those at increased risk of 
contacting or spreading the infection (10, 11). The 
United States was the first to follow the WHO recom-
mendation.
The rationale for vaccine control against  
VZV infection 
Varicella is an extremely contagious disease experi-
enced by almost every child or young adult in the world. 
Four million cases had occurred every year in the United 
States in 1990-1994 before the introduction of a vaccina-
tion; nearly 10,000 patients had required hospitalization 
and 100 patients had died (10). A cost-benefit analysis 
in the United States showed that routine varicella vacci-
nation is likely to save 5 times the investment (12). Even 
when only direct costs were considered, benefits almost 
balanced the costs (10, 13, 14).
After the general recommendation of one-dose va-
ricella vaccination for routine use for children aged 12 
months and above in the United States in 1995, signifi-
cant improvement has been seen in the number of va-
ricella cases, varicella-related ambulatory visits, hospi-
talization and deaths. By the year 2000, the incidence 
of disease had decreased by 75% (coverage rate 84%) 
and 75-80% reduction of hospital treatment could have 
been achieved. Varicella-related deaths had decreased 
by 75-92% in children and adolescents and by 74% in 
adults (15). However, the problem of breakthrough vari-
cella cases, defined as the appearance of pruritic mac-
ulo-papulo-vesicular rash, occurring after more than 
42 days after vaccination with no other apparent cause 
has remained (13). Breakthrough varicella is caused by 
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primary (PVF) or secondary vaccine failure (SVF) (PVF: 
the failure to give a protective immune response after 
vaccination; SVF: the gradual waning of immunity over 
time).
Several questions are raised on VZV vaccination
Is the safety and efficacy profile of the vaccines ad-
equate for nationwide application? Which vaccination 
schedules could be preferred? How to fit the schedule 
chosen into the NIP?
In response to the increasing number of break-
through varicella cases, several countries have imple-
mented recommendations for a two-dose varicella vac-
cination schedule (16).
In the current universal routine vaccination (URV) 
recommendation, the routine childhood schedule in-
cludes the first dose at the age of 12-15 months and the 
second dose at the age of 4-6 years or 15-23 months 
(minimum interval of 3 months). For adolescents (> 13 
years) and adults, two doses are recommended 4-8 
weeks apart in those with no evidence of immunity. The 
second dose should be given for all persons without 
the history of breakthrough varicella who previously re-
ceived one dose.
Timing of the second dose varies in different coun-
tries from the age of 4-6 years (e.g. Greece, Israel, Saudi 
Arabia, the United States) to the age of 15-23 months 
(e.g. Germany, Hungary, Luxembourg).
Besides the epidemiological aspect, the vaccina-
tion, as a primary preventive technique, has been anal-
ysed from health economic perspective raising further 
questions.
Health economic considerations: is primary  
prevention cost-effective or cost-saving?
In the long-term, health care expenditure grows 
faster than GDP (as a result of growing expectations 
with income growth, aging population, easier access to 
health care due to insurance coverage etc.). In challeng-
ing economic periods, governments tend to implement 
cost-containment measures in the health sector. Even 
in those periods, when health care budgets are seri-
ously restricted, further resources for primary prevention 
should be found. 
Primary prevention programmes improve the effi-
ciency of health care programmes by different means. 
They may improve the equity of health care provi-
sion, especially if certain screening or vaccination 
programmes are mandated or targeted for those sub-
populations with greater health needs. Preventive pro-
grammes positively influence the health behaviour of 
patients, and consequently can lead to patients taking 
a more active part in their health care, reducing their 
moral hazard. Moral hazard means that, as patients 
have zero or minimal personal financial contribution 
when accessing health care services related to their 
own disease, they do not pay attention to the price 
and quantity of health care technologies, they rely too 
much on the solidarity of the community (i.e. payers 
of health insurance premiums). Preventive services, in-
cluding vaccination programmes can help societies to 
reassess the solidarity principle, as they emphasise the 
importance of personal investment into people’s own 
health, and the adherence to guidelines and therapeu-
tic advice.
Clinical opinion leaders and policy-makers have to 
understand that primary prevention is mostly cost-effec-
tive without being cost-saving. Credible and methodo-
logically solid health economic analyses can increase 
the social priority of primary prevention including vac-
cination programmes. However, in order to facilitate 
cooperation with policy-makers and payers, clinicians 
have to accept that registered indication is not equal to 
reimbursed indication, and not every innovative therapy 
is available for every patient immediately.
A general objection of payers is the lack of long-
term experience with a new innovative preventive or 
therapeutic technology. It should be kept in mind, 
however, that it is impossible to present these long-
term data at the launch of preventive health care pro-
grams. In preventive medicine, we cannot wait for 
confirmatory evidence (e.g. cannot investigate what 
happens if in one-year influenza is not controlled 
vs. the next controlled year), so we have to accept 
a reasonable health economic modeling approach. 
Of note, uncertainty for vaccines is still less than for 
many other health technologies (e.g. surgical inter-
ventions, medical devices etc.) or food products. The 
immunological response and safety of vaccines have 
to be tested in clinical trials. There are no mandatory 
clinical trial criteria for new surgical methods, medical 
devices or food ingredients. For varicella vaccination, 
however, real-world experience is available to validate 
our approach.
Health economic considerations: modelling  
techniques to estimate the benefits of vaccines
To estimate the benefits of vaccines, modelling is 
required, since vaccine clinical trials are in some cases 
limited to immune efficacy; duration of protection is 
usually unknown (induction and duration of immuno-
logical memory); epidemiology of disease is often not 
known, and we cannot wait for evidence on real pan-
demics; the efficacy measured from randomized con-
trolled trials (RCTs) is subject to different transmission 
settings, as we cannot control the spread of disease; 
long-term benefits are not directly captured; and popu-
lation effectiveness could be different from individual 
efficacy, especially due to herd immunity. 
The optimal vaccination strategies (routine, at risk, 
versus epidemiological barrier, etc.) should also be de-
termined by modelling techniques.
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2Varivax is a trade mark of Sanofi Pasteur MSD.
A general objection by payers is that modelling is 
only hypothetical extrapolation. Considering only short 
time horizon may underestimate the real value of in-
vestment into health, and this is especially true for vac-
cines. Therefore we have to choose such time horizon 
that enables all consequences in terms of costs and 
outcomes to be taken into account (e.g. lifetime ben-
efits). Health economic modelling, with thorough sen-
sitivity analysis, reduces the uncertainty of reimburse-
ment decisions compared to alternative use of public 
resources.
Moving towards universal varicella vaccination:  
the German experience
In the pre-vaccination area, the incidence of VZV 
infection was about 760,000 varicella cases per year 
in Germany. Vaccines became available in 19951 and 
20042. The goals of varicella vaccination strategy were 
declared: (1) to reduce the rate of morbidity, complica-
tions, hospitalizations and mortality; (2) to protect sus-
ceptible high-risk patients by herd immunity; (3) to elimi-
nate varicella in the long-term; and (4) to save medical 
and societal costs.
The health economic project to calculate clinical 
benefits and cost-effectiveness of a universal vaccina-
tion program consisted of seroprevalence and epide-
miological studies, as well as health economic mod-
elling (to assess the potential clinical and economic 
effects of a universal varicella vaccination program vs. 
no vaccination).
The possible vaccination strategies are: (1) children 
strategy (universal vaccination of children at the age 
of 15 months; (2) adolescent strategy (vaccination of 
susceptible persons at the age of 11-15 years; and 
(3) combined strategy (vaccination of children at the 
age of 15 months and of susceptible persons at the 
age of 11-12 years). Economic analyses have shown 
that universal mass vaccination of infants using a one-
dose schedule is cost-saving in Germany) (17). Ac-
cording to a 10-year follow-up, two doses of varicella 
vaccine have been shown to be more effective than 
one dose and to reduce varicella breakthrough rates 
(18). Basingon the newly available data, the German 
Standing Committee on Vaccination (STIKO) modified 
its recommendations for varicella vaccination in July 
2009. The recommendation for varicella vaccination 
now includes a routine two-dose schedule with the 
administration of the first dose at the age of 11 to 14 
months and the second dose at the age of 15 to 23 
months, with a minimum interval of four to six weeks 
between these doses.
CONCLUSIONS
1. Varicella causes a significant medical and economic 
burden. Improving the present unfavorable epidemi-
ological situation is needed in both countries. Many 
limiting factors for data collection exist (varicella is 
currently underreported), more focus on prevention 
and proper infrastructure is needed. Vaccine up-
take seems to be mainly limited by the lack of broad 
health-consciousness of general public, the lack of 
reimbursement and parents’ financial capabilities.
2. The role of health economics is important. Assess-
ment of cost-effectiveness and budget impact can 
facilitate the match of optimal vaccination strategy 
with efficient and sustainable health care financing. 
Before implementing a new vaccination strategy, hy-
potheses and assumptions have to be made, and all 
of them need economic modelling. At present, broad 
access to the vaccines seems to be limited mostly for 
budgetary reasons, besides the scarcity of informa-
tion on the part of doctors and patients. Partial reim-
bursement could also be satisfactory after modelling 
possible scenarios – if full reimbursement could not 
be achieved.
3. Reimbursement could not only give parents financial 
support to access the vaccine but also help them 
consider varicella vaccine as important, as reimburse-
ment is an explicit indicator of public health priorities. 
It is expected to lead to higher vaccine uptake and 
consequently decrease theburden of disease. As the 
first step, the best vaccination schedule that fits into 
the national vaccination calendar should be defined. 
The most appropriate recommendation would be to 
vaccinate children in their second year of life. 
4. There are several options for the improvement of the 
access to vaccines:
a) Full reimbursement of two doses of varicella vac-
cine for one or more cohortswould bean ideal situ-
ation.
If this is not feasible, other options could be:
b) Partial reimbursement scheme for one or more 
cohorts:
 – the same reimbursement rate for both doses 
(e. g. 50%);
 – the first dose with no reimbursement, the sec-
ond dose with full reimbursement.
c) Reimbursement for high-risk groups or persons 
from an environment of risk groups (this is already 
available in Poland).
5. Whichever solution is chosen, significant education 
of the health care workers, parents and patients is 
crucial. 
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